Previous close | 85.94 |
Open | 86.54 |
Bid | 0.00 x 1100 |
Ask | 87.89 x 800 |
Day's range | 85.73 - 87.11 |
52-week range | 60.57 - 96.12 |
Volume | |
Avg. volume | 4,034,369 |
Market cap | 52.344B |
Beta (5Y monthly) | 1.07 |
PE ratio (TTM) | 37.81 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Edwards Lifesciences fair value estimate is US$76.62 With...